18 stories found
Several companies, including Havas, Aegon, and MTN, have announced updates regarding their share buyback programs. These announcements detail ongoing transactions and expansions of existing buyback initiatives.
Zealand Pharma has reported its GAAP Earnings Per Share (EPS) at DKK55.34 and revenue of DKK4.49 billion.
Zealand Pharma's stock experienced a climb after the company announced a new share buyback program.
Zealand Pharma has announced the appointment of Eric Rojas as its new Vice President and Head of Investor Relations.
Zealand Pharma's shares dropped significantly by 32% following disappointing mid-stage trial results for a weight-loss treatment being developed with Roche.
Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial WSJ
Zealand Pharma has issued a notification regarding its holding of treasury shares.
New weight-loss drugs are facing increased scrutiny as a trial for Zealand Pharma's experimental drug caused its stock to tumble due to safety concerns, while another report highlighted a potential muscle loss side effect, dubbed 'Ozempic butt.' These developments are impacting investor confidence and raising questions about the safety profiles of these medications.
Zealand Pharma announced that its GLP-1 drug, developed in collaboration with Boehringer Ingelheim, achieved an average of 17% weight loss in participants during a late-stage clinical trial.
Investorerne er langt fra tilfredse med de vægttabsdata, som Zealand Pharma har offentliggjort for nyt middel.
Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market WSJ
Shares in Zealand Pharma experienced a significant drop on the stock exchange following the release of disappointing data from its weight-loss drug trials.
Zealand Pharma announced transactions related to its share buy-back program for week 33, 2026.
Zealand Pharma and FLSmidth have announced transactions related to their respective share buy-back programs. These transactions occurred during week 22 of 2026.
A drug developed by Boehringer Ingelheim and Zealand Pharma demonstrated an average of 16.6% weight loss in patients during a late-stage clinical trial, indicating potential for obesity treatment.
Despite a significant share price drop, Zealand Pharma's CEO remains optimistic, while Novo Nordisk anticipates competition from cheaper generic versions of its weight-loss drugs entering major markets this year.
Zealand Pharma's CEO states that the most tolerable drugs will be the next to succeed in the obesity market.
Zealand Pharma has released its financial results for the full fiscal year.